Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Abstract: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM. We describe...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001594
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items